Hypofractionated Intensity Modulated Chemoradiotherapy to Treat Locally Advanced Non-Small Cell Lung Cancer

Phase II Study on Dose Escalated, Accelerated Hypofractionated Intensity Modulated Radiotherapy for Stage III Non-Small Cell Lung Cancer With Concurrent Chemotherapy

Status

UNKNOWN

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00938418

Enrollment

Registered

2009-07-13

Start date

2009-07-31

Completion date

Unknown

Last updated

2009-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stage III Non-Small Cell Lung Cancer

Brief summary

Locally advanced non-small cell lung cancer can be treated successfully with chemotherapy and radiation. However, the cure rate is low. This study is carried out to find out whether giving radiotherapy at a higher dose over fewer treatment sessions with intensity modulated radiotherapy (IMRT) can improve the treatment outcome. This study aims to recruit 43 patients from National University Hospital and Tan Tock Seng Hospital over a period of about 2 years.

Interventions

RADIATIONDose escalated, accelerated, hypofractionated radiotherapy

Intensity modulated radiotherapy with concurrent chemotherapy

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

21 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Pathologically proven (either histologic or cytologic) diagnosis of Stage IIIA or IIIB non-small cell lung cancer; excluding patients with N3 disease based on supraclavicular or contralateral hilar adenopathy, or significant pleural / pericardial effusion.

Exclusion criteria

* Patients for whom treatment is planned with a maximum dose of ≥ 66 Gy to the ipsilateral brachial plexus * Greater than minimal, exudative, or cytologically positive pleural effusions * ≥ 10% weight loss within the past month * Prior invasive malignancy (with exceptions) * Prior radiotherapy to the region of the study cancer * Significant co-morbidities * Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception * Known allergic reactions to components of planned chemotherapy regimen

Design outcomes

Primary

Measure	Time frame
Overall survival	2 years

Secondary

Measure	Time frame
Response rate, locoregional control, disease free survival, toxicity	2 years

Countries

Singapore

Contacts

Primary ContactIvan Tham, MD

ivan_wk_tham@nuh.com.sg6567724870

Backup ContactJay Lu, MD

6567724870

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026